1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. North America Biopharmaceuticals Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. North America Biopharmaceuticals Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1 Advancements in gene therapies
- 5.1.2 Rising demand for personalized medicine
- 5.1.3 Growth in biologic drug development
5.2 Market Opportunities
- 5.2.1 Rising demand for biologics in treating chronic diseases
- 5.2.2 Expanding market for targeted therapies
- 5.2.3 Growth in gene and cell therapies
5.3 Future Trends
- 5.3.1 Expansion of biologics for treating rare and chronic diseases
- 5.3.2 Growing adoption of biologic drugs in oncology and immunology
- 5.3.3 Advancements in genetic and cell-based therapies
5.4 Impact of Drivers and Restraints
6. North America Biopharmaceuticals Market Regional Analysis
6.1 North America Biopharmaceuticals Market Overview
6.2 North America Biopharmaceuticals Market Revenue 2020-2028 (US$ Billion)
6.3 North America Biopharmaceuticals Market Forecast Analysis
7. North America Biopharmaceuticals Market Analysis – by Product Type
7.1 Monoclonal Antibodies
- 7.1.1 Overview
- 7.1.2 Monoclonal Antibodies: North America Biopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Billion)
7.2 Recombinant Vaccines
- 7.2.1 Overview
- 7.2.2 Recombinant Vaccines: North America Biopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Billion)
7.3 Conventional Vaccines
- 7.3.1 Overview
- 7.3.2 Conventional Vaccines: North America Biopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Billion)
7.4 Recombinant Growth Factors
- 7.4.1 Overview
- 7.4.2 Recombinant Growth Factors: North America Biopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Billion)
7.5 Purified Proteins
- 7.5.1 Overview
- 7.5.2 Purified Proteins: North America Biopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Billion)
7.6 Recombinant Proteins
- 7.6.1 Overview
- 7.6.2 Recombinant Proteins: North America Biopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Billion)
7.7 Recombinant Hormones
- 7.7.1 Overview
- 7.7.2 Recombinant Hormones: North America Biopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Billion)
7.8 Recombinant Enzymes
- 7.8.1 Overview
- 7.8.2 Recombinant Enzymes: North America Biopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Billion)
7.9 Cell & Gene Therapies
- 7.9.1 Overview
- 7.9.2 Cell & Gene Therapies: North America Biopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Billion)
7.10 Cytokines/Interferon/Interleukins
- 7.10.1 Overview
- 7.10.2 Cytokines/Interferon/Interleukins: North America Biopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Billion)
8. North America Biopharmaceuticals Market Analysis – by Application
8.1 Oncology
- 8.1.1 Overview
- 8.1.2 Oncology: North America Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Billion)
8.2 Inflammatory & Infectious Disease
- 8.2.1 Overview
- 8.2.2 Inflammatory & Infectious Disease: North America Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Billion)
8.3 Autoimmune Disorders
- 8.3.1 Overview
- 8.3.2 Autoimmune Disorders: North America Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Billion)
8.4 Metabolic Disorders
- 8.4.1 Overview
- 8.4.2 Metabolic Disorders: North America Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Billion)
8.5 Hormonal Disorders & Growth Failure
- 8.5.1 Overview
- 8.5.2 Hormonal Disorders & Growth Failure: North America Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Billion)
8.6 Cardiovascular Diseases
- 8.6.1 Overview
- 8.6.2 Cardiovascular Diseases: North America Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Billion)
8.7 Neurological Diseases
- 8.7.1 Overview
- 8.7.2 Neurological Diseases: North America Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Billion)
9. North America Biopharmaceuticals Market – North America Analysis
9.1 North America
- 9.1.1 North America Biopharmaceuticals Market Breakdown, by Key
Country, 2023 and 2028 (%)
- 9.1.1.1 North America Biopharmaceuticals Market – Revenue and
Forecast Analysis – by Country
- 9.1.1.1 US:
North America Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Billion)
- 9.1.1.1.1 US: North America Biopharmaceuticals Market Breakdown, by Product Type
- 9.1.1.1.2 US: North America Biopharmaceuticals Market Breakdown, by Application
- 9.1.1.2 Canada:
North America Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Billion)
- 9.1.1.2.1 Canada: North America Biopharmaceuticals Market Breakdown, by Product Type
- 9.1.1.2.2 Canada: North America Biopharmaceuticals Market Breakdown, by Application
- 9.1.1.3 Mexico :
North America Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Billion)
- 9.1.1.3.1 Mexico : North America Biopharmaceuticals Market Breakdown, by Product Type
- 9.1.1.3.2 Mexico : North America Biopharmaceuticals Market Breakdown, by Application
10. Competitive Landscape
10.1 Heat Map Analysis
10.2 Company Positioning and Concentration
11. North America Biopharmaceuticals Market Industry Landscape
11.1 Overview
11.2 Mergers and Acquisitions
11.3 Agreements, Collaborations, and Joint Ventures
11.4 New Product Launches
11.5 Expansions and Other Strategic Developments
12. Company Profiles
12.1 AbbVie Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 AGC Biologics AS
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Amgen Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Boehringer Ingelheim International GmbH
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Bristol-Myers Squibb Co
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Eli Lilly and Co
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Johnson & Johnson
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Lonza Group AG
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Thermo Fisher Scientific Inc
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 WuXi Biologics Inc
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
13. Appendix
13.1 About Business Market Insights
Get Free Sample For North America Biopharmaceuticals Market
